Ovid Therapeutics (OVID) Scheduled to Post Earnings on Thursday
Ovid Therapeutics (NASDAQ:OVID) is scheduled to be posting its quarterly earnings results after the market closes on Thursday, March 29th. Analysts expect Ovid Therapeutics to post earnings of ($0.38) per share for the quarter.
Shares of Ovid Therapeutics stock opened at $7.85 on Thursday. Ovid Therapeutics has a fifty-two week low of $5.28 and a fifty-two week high of $15.93.
Several analysts have commented on the company. ValuEngine upgraded Ovid Therapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday, December 31st. Zacks Investment Research upgraded Ovid Therapeutics from a “hold” rating to a “buy” rating and set a $11.00 price target for the company in a report on Friday, January 12th. Finally, Piper Jaffray Companies assumed coverage on Ovid Therapeutics in a report on Friday, March 9th. They issued an “overweight” rating and a $20.00 price target for the company. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $19.50.
TRADEMARK VIOLATION WARNING: “Ovid Therapeutics (OVID) Scheduled to Post Earnings on Thursday” was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The legal version of this report can be read at https://www.watchlistnews.com/ovid-therapeutics-ovid-scheduled-to-post-earnings-on-thursday/1954669.html.
Ovid Therapeutics Company Profile
Ovid Therapeutics Inc (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist.
Receive News & Ratings for Ovid Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.